Evidence map›Paper›PMID 41749924›Full record

ArticleCancers2026

Prognostic Impact of Baseline Neutrophil-to-Lymphocyte Ratio and Its On-Treatment Change on Survival Outcomes in Advanced Small-Cell Lung Cancer: A Retrospective Analysis.

Masashi Ishihara, Hao Chen, Reina Asaga, Hikaru Suzuki, Shinichiro Yamamoto, Maju Kawamoto, Hitoshi Hoshiya, Hiroki Kazahari, Ryosuke Ochiai, Shigeru Tanzawa and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Masashi IshiharaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Hao ChenChemotherapy Center, Yokohama Minami Kyosai Hospital, Yokohama 236-0037, Japan.ORCID 0000-0003-3074-2235
Reina AsagaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Hikaru SuzukiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Shinichiro YamamotoDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Maju KawamotoDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Hitoshi HoshiyaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Hiroki KazahariDivision of Respiratory Medicine, The Fraternity Memorial Hospital, Sumida 130-8587, Japan.
Ryosuke OchiaiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Shigeru TanzawaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.ORCID 0000-0001-5738-0313
Takeshi HondaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Yasuko IchikawaDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.
Kiyotaka WatanabeDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.ORCID 0000-0001-9332-8328
Nobuhiko SekiDivision of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Itabashi 173-8606, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReliable and readily accessible prognostic biomarkers for extensive-stage small-cell lung cancer (ES-SCLC) are still lacking. The neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, has shown prognostic relevance in several malignancies; however, its dynamic changes during treatment have not been well characterized in SCLC.

methodsWe retrospectively analyzed patients with ES-SCLC who received systemic chemotherapy between January 2010 and December 2024. Baseline NLR was calculated within 7 days before first-line treatment, and on-treatment NLR was assessed at 6 weeks. A predefined NLR cutoff value of 5 was applied, and changes in NLR (ΔNLR) were defined as the difference between 6-week and baseline values. Associations with time to treatment failure (TTF) and overall survival (OS) were evaluated.

resultsA total of 176 patients were enrolled. High baseline NLR (≥5) was significantly associated with shorter TTF and OS (both

conclusionsCombined evaluation of baseline NLR and its on-treatment change provides improved prognostic stratification in patients with ES-SCLC.

Indexed as

biomarkersneutrophil-to-lymphocyte ratiosmall cell lung cancersystemic inflammation

Identifiers

PMID41749924
PMCPMC12939829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.